BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 28652249)

  • 1. WEE1 Kinase Inhibitor AZD1775 Has Preclinical Efficacy in LKB1-Deficient Non-Small Cell Lung Cancer.
    Richer AL; Cala JM; O'Brien K; Carson VM; Inge LJ; Whitsett TG
    Cancer Res; 2017 Sep; 77(17):4663-4672. PubMed ID: 28652249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint.
    Lin X; Chen D; Zhang C; Zhang X; Li Z; Dong B; Gao J; Shen L
    J Exp Clin Cancer Res; 2018 Jun; 37(1):129. PubMed ID: 29954437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PARP1 Trapping and DNA Replication Stress Enhance Radiosensitization with Combined WEE1 and PARP Inhibitors.
    Parsels LA; Karnak D; Parsels JD; Zhang Q; VĂ©lez-Padilla J; Reichert ZR; Wahl DR; Maybaum J; O'Connor MJ; Lawrence TS; Morgan MA
    Mol Cancer Res; 2018 Feb; 16(2):222-232. PubMed ID: 29133592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting AXL and mTOR Pathway Overcomes Primary and Acquired Resistance to WEE1 Inhibition in Small-Cell Lung Cancer.
    Sen T; Tong P; Diao L; Li L; Fan Y; Hoff J; Heymach JV; Wang J; Byers LA
    Clin Cancer Res; 2017 Oct; 23(20):6239-6253. PubMed ID: 28698200
    [No Abstract]   [Full Text] [Related]  

  • 5. Wee1 Kinase Inhibitor AZD1775 Radiosensitizes Hepatocellular Carcinoma Regardless of TP53 Mutational Status Through Induction of Replication Stress.
    Cuneo KC; Morgan MA; Davis MA; Parcels LA; Parcels J; Karnak D; Ryan C; Liu N; Maybaum J; Lawrence TS
    Int J Radiat Oncol Biol Phys; 2016 Jun; 95(2):782-90. PubMed ID: 26975930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Wee1 inhibitor MK1775 sensitizes KRAS mutated NSCLC cells to sorafenib.
    Caiola E; Frapolli R; Tomanelli M; Valerio R; Iezzi A; Garassino MC; Broggini M; Marabese M
    Sci Rep; 2018 Jan; 8(1):948. PubMed ID: 29343688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strategic development of AZD1775, a Wee1 kinase inhibitor, for cancer therapy.
    Fu S; Wang Y; Keyomarsi K; Meric-Bernstam F; Meric-Bernstein F
    Expert Opin Investig Drugs; 2018 Sep; 27(9):741-751. PubMed ID: 30102076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A WEE1 Inhibitor Analog of AZD1775 Maintains Synergy with Cisplatin and Demonstrates Reduced Single-Agent Cytotoxicity in Medulloblastoma Cells.
    Matheson CJ; Venkataraman S; Amani V; Harris PS; Backos DS; Donson AM; Wempe MF; Foreman NK; Vibhakar R; Reigan P
    ACS Chem Biol; 2016 Apr; 11(4):921-30. PubMed ID: 26745241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PAXIP1 Potentiates the Combination of WEE1 Inhibitor AZD1775 and Platinum Agents in Lung Cancer.
    Jhuraney A; Woods NT; Wright G; Rix L; Kinose F; Kroeger JL; Remily-Wood E; Cress WD; Koomen JM; Brantley SG; Gray JE; Haura EB; Rix U; Monteiro AN
    Mol Cancer Ther; 2016 Jul; 15(7):1669-81. PubMed ID: 27196765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metformin Enhances Cisplatin-Induced Apoptosis and Prevents Resistance to Cisplatin in Co-mutated KRAS/LKB1 NSCLC.
    Moro M; Caiola E; Ganzinelli M; Zulato E; Rulli E; Marabese M; Centonze G; Busico A; Pastorino U; de Braud FG; Vernieri C; Simbolo M; Bria E; Scarpa A; Indraccolo S; Broggini M; Sozzi G; Garassino MC
    J Thorac Oncol; 2018 Nov; 13(11):1692-1704. PubMed ID: 30149143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual Targeting of WEE1 and PLK1 by AZD1775 Elicits Single Agent Cellular Anticancer Activity.
    Wright G; Golubeva V; Remsing Rix LL; Berndt N; Luo Y; Ward GA; Gray JE; Schonbrunn E; Lawrence HR; Monteiro ANA; Rix U
    ACS Chem Biol; 2017 Jul; 12(7):1883-1892. PubMed ID: 28557434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutational status of
    Ku BM; Bae YH; Koh J; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Oncotarget; 2017 Sep; 8(40):67526-67537. PubMed ID: 28978051
    [No Abstract]   [Full Text] [Related]  

  • 13. Synergy of WEE1 and mTOR Inhibition in Mutant
    Hai J; Liu S; Bufe L; Do K; Chen T; Wang X; Ng C; Li S; Tsao MS; Shapiro GI; Wong KK
    Clin Cancer Res; 2017 Nov; 23(22):6993-7005. PubMed ID: 28821559
    [No Abstract]   [Full Text] [Related]  

  • 14. Bromodomain and extraterminal domain inhibition synergizes with WEE1-inhibitor AZD1775 effect by impairing nonhomologous end joining and enhancing DNA damage in nonsmall cell lung cancer.
    Takashima Y; Kikuchi E; Kikuchi J; Suzuki M; Kikuchi H; Maeda M; Shoji T; Furuta M; Kinoshita I; Dosaka-Akita H; Sakakibara-Konishi J; Konno S
    Int J Cancer; 2020 Feb; 146(4):1114-1124. PubMed ID: 31199520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular Pathways: Targeting the Protein Kinase Wee1 in Cancer.
    Geenen JJJ; Schellens JHM
    Clin Cancer Res; 2017 Aug; 23(16):4540-4544. PubMed ID: 28442503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Wee1 Kinase Inhibitor AZD1775 Effectively Sensitizes Esophageal Cancer to Radiotherapy.
    Yang L; Shen C; Pettit CJ; Li T; Hu AJ; Miller ED; Zhang J; Lin SH; Williams TM
    Clin Cancer Res; 2020 Jul; 26(14):3740-3750. PubMed ID: 32220892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of Potent Pyrazolopyrimidinone-Based WEE1 Inhibitors with Limited Single-Agent Cytotoxicity for Cancer Therapy.
    Matheson CJ; Casalvieri KA; Backos DS; Reigan P
    ChemMedChem; 2018 Aug; 13(16):1681-1694. PubMed ID: 29883531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutant LKB1 Confers Enhanced Radiosensitization in Combination with Trametinib in KRAS-Mutant Non-Small Cell Lung Cancer.
    Wang Y; Li N; Jiang W; Deng W; Ye R; Xu C; Qiao Y; Sharma A; Zhang M; Hung MC; Lin SH
    Clin Cancer Res; 2018 Nov; 24(22):5744-5756. PubMed ID: 30068711
    [No Abstract]   [Full Text] [Related]  

  • 19. Co-occurring KRAS mutation/LKB1 loss in non-small cell lung cancer cells results in enhanced metabolic activity susceptible to caloric restriction: an in vitro integrated multilevel approach.
    Caiola E; Falcetta F; Giordano S; Marabese M; Garassino MC; Broggini M; Pastorelli R; Brunelli L
    J Exp Clin Cancer Res; 2018 Dec; 37(1):302. PubMed ID: 30514331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LKB1 inactivation sensitizes non-small cell lung cancer to pharmacological aggravation of ER stress.
    Inge LJ; Friel JM; Richer AL; Fowler AJ; Whitsett T; Smith MA; Tran NL; Bremner RM
    Cancer Lett; 2014 Oct; 352(2):187-95. PubMed ID: 25011082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.